Cardiac Analysis of Autologous Transplantation of Cocultured Skeletal Myoblasts and Mesenchymal Cells in a Rat Model Doxorubicin-Induced Cardiotoxicity: Histopathological and Functional Studies

Introduction:

Cancer affects more than 1.6 million of Americans and is believed to be the second most common cause of death (after accidents, injuries and intoxication) in children. Unfortunately, cardiotoxicity is the most severe of chronic complications of antineoplastic therapy. Doxorubicin (DOX) is an anthracycline effective antitumor agent used in cancer treatment and the most widely used and successful chemotherapeutic for childhood cancers. However, its clinical use is limited due to its severe and irreversible cardiotoxicity including the development of cardiomyopathy, and ultimately congestive heart failure .

The significant advances in therapeutic modalities, such as heart or ventricular transplantation, have emerged in the field of regenerative medicine with the use of mesenchymal stem cells (MSCs). During the past decade, it has been demonstrated that MSCs possess outstanding potential for cardiac regeneration based on their multipotential differentiation ability, easy tissue accessibility and capacity for ex-vivo expansion.

Transplantation of satellite cell-derived myoblasts has therapeutic potential for repairing damaged heart and has been used both, experimentally and clinically, in an attempt to restore cardiac function. Therefore, transplantation of cocultured cells remains an attractive approach for myocardial repair.

So, the current study was conducted to evaluate the functional and histopathological effect of combined transplantation of MSCs and SM in doxorubicin-induced cardiomyopathy.